First-line anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy in Japanese mucosal melanoma: A retrospective, multicenter study (JMAC study)

被引：0

作者：

Nakamura, Y. ^{[1
]}

Namikawa, K. ^{[2
]}

Yoshikawa, S. ^{[3
]}

Kiniwa, Y. ^{[4
]}

Maekawa, T. ^{[5
]}

Yamasaki, O. ^{[6
]}

Isei, T. ^{[7
]}

Matsushita, S. ^{[8
]}

Nomura, M. ^{[9
]}

Nakai, Y. ^{[10
]}

Fukushima, S. ^{[11
]}

Saito, S. ^{[12
]}

Takenouchi, T. ^{[13
]}

Tanaka, R. ^{[14
]}

Kato, H. ^{[15
]}

Otsuka, A. ^{[16
]}

Matsuya, T. ^{[17
]}

Baba, N. ^{[18
]}

Nagase, K. ^{[19
]}

Inozume, T. ^{[20
]}

机构：

[1] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, Saitama, Japan

[2] Natl Canc Ctr Hosp Tsukiji Campus, Dept Dermatol Oncol, Tokyo, Japan

[3] Shizuoka Canc Ctr, Dept Dermatol, Shizuoka, Japan

[4] Shinshu Univ, Dept Dermatol, Matsumoto, Nagano, Japan

[5] Jichi Med Univ Hosp, Dept Dermatol, Shimotsuke, Tochigi, Japan

[6] Okayama Univ, Dept Dermatol, Okayama, Japan

[7] Osaka Int Canc Inst, Dept Dermatol Oncol, Osaka, Japan

[8] Natl Hosp Org, Kagoshima Med Ctr, Dept Dermatooncol Dermatol, Kagoshima, Japan

[9] Kyoto Univ, Grad Sch Med, Dept Therapeut Oncol, Kyoto, Japan

[10] Mie Univ, Dept Dermatol, Tsu, Mie, Japan

[11] Kumamoto Univ, Dept Dermatol, Kumamoto, Japan

[12] Gunma Univ, Dept Dermatol, Maebashi, Gumma, Japan

[13] Niigata Canc Ctr Hosp, Dept Dermatol, Niigata, Japan

[14] Kawasaki Med Sch, Dept Dermatol, Kurashiki, Okayama, Japan

[15] Nagoya City Univ, Dept Dermatol, Nagoya, Aichi, Japan

[16] Kyoto Univ Hosp, Dept Dermatol, Kyoto, Japan

[17] Asahikawa Med Univ, Dept Dermatol, Asahikawa, Hokkaido, Japan

[18] Univ Fukui, Dept Dermatol, Fukui, Japan

[19] Saga Univ, Dept Dermatol, Saga, Japan

[20] Chiba Univ, Dept Dermatol, Chiba, Japan

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1431

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1046P

引用

页码：S876 / S876

页数：1

共 50 条

[41] Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’
Keisuke Imafuku
Koji Yoshino
Kei Yamaguchi
Satoshi Tsuboi
Kuniaki Ohara
Hiroo Hata
[J]. British Journal of Cancer, 2017, 116 : e14 - e14
[42] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy
Prithviraj, Prashanth
McArthur, Grant A.
Atkinson, Victoria
Parente, Phillip
Andrews, Miles Cameron
Parakh, Sagun
Cebon, Jonathan S.
Klein, Oliver
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[43] Effects of Combination of Anti-CTLA-4 and Anti-PD-1 on Gastric Cancer Cells Proliferation, Apoptosis and Metastasis
Wang, Bin
Qin, Lei
Ren, Mei
Sun, Hao
[J]. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 49 (01) : 260 - 270
[44] Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials
Hao, Chunyan
Tian, Jinhui
Liu, Huiling
Li, Fei
Niu, Hongxia
Zhu, Bingdong
[J]. MEDICINE, 2017, 96 (26)
[45] S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
Wagner, Nikolaus B.
Forschner, Andrea
Leiter, Ulrike
Garbe, Claus
Eigentler, Thomas K.
[J]. BRITISH JOURNAL OF CANCER, 2018, 119 (03) : 339 - 346
[46] S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
Nikolaus B Wagner
Andrea Forschner
Ulrike Leiter
Claus Garbe
Thomas K Eigentler
[J]. British Journal of Cancer, 2018, 119 : 339 - 346
[47] Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
Seidel, Judith A.
Otsuka, Atsushi
Kabashima, Kenji
[J]. FRONTIERS IN ONCOLOGY, 2018, 8
[48] Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
Stratigos, Alexander J.
Sekulic, Aleksandar
Peris, Ketty
Bechter, Oliver
Prey, Sorilla
Kaatz, Martin
Lewis, Karl D.
Basset-Seguin, Nicole
Chang, Anne Lynn S.
Dalle, Stephane
Orland, Almudena Fernandez
Licitra, Lisa
Robert, Caroline
Ulrich, Claas
Hauschild, Axel
Migden, Michael R.
Dummer, Reinhard
Li, Siyu
Yoo, Suk-Young
Mohan, Kosalai
Coates, Ebony
Jankovic, Vladimir
Fiaschi, Nathalie
Okoye, Emmanuel
Bassukas, Ioannis D.
Loquai, Carmen
De Giorgi, Vincenzo
Eroglu, Zeynep
Gutzmer, Ralf
Ulrich, Jens
Puig, Susana
Seebach, Frank
Thurston, Gavin
Weinreich, David M.
Yancopoulos, George D.
Lowy, Israel
Bowler, Timothy
Fury, Matthew G.
[J]. LANCET ONCOLOGY, 2021, 22 (06): : 848 - 857
[49] ENHANCED ANTI-TUMOR EFFECTS OF ANTI-CTLA-4 ANTIBODY AND ANTI-PD-1 ANTIBODY TO KIDNEY CANCER MODEL IN MICE
Motoshima, Takanobu
Komohara, Yoshihiro
Hasita, Horlad
Kawano, Yoshiaki
Wada, Yoshihiro
Takeya, Motohiro
Eto, Masatoshi
[J]. JOURNAL OF UROLOGY, 2014, 191 (04): : E372 - E373
[50] Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, Spencer
Levine, Jacob
Cogdill, Alexandria
Zhao, Yang
Anang, Nana-Ama
Andrews, Miles
Sharma, Padmanee
Wang, Jing
Wargo, Jennifer
Pe'er, Dana
Allison, James
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5

← 1 2 3 4 5 →